Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392927 | 0.86 | HSP90AB1 (0.42) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22988101 | 0.86 | HSP90AB1 (0.42) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22987758 | 0.85 | ALDH1A1 (0.40) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22987811 | 0.84 | ADORA3 (0.36) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL30393466 | 0.84 | ADORA3 (0.36) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22987794 | 0.83 | KDM4E (0.43) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22987615 | 0.83 | ADORA3 (0.36) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22979953 | 0.80 | KDM4E (0.49) | ADORA3ADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL22987727 | 0.78 | TP53 (0.39) | ADORA3KDM4EALDH1A1HPGDCOMT | |
| SCHEMBL22979312 | 0.75 | ADORA2A (0.33) | ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA3 34/4885ADORA2A 103/4885ADORA1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.